Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue        
Product revenue, net $ 9,447 $ 9,492 $ 30,808 $ 23,816
Revenue - related party 28 280 1,042 1,683
Net revenue 9,475 9,772 31,850 25,499
Operating expenses        
Cost of goods sold - product revenue 3,379 2,702 10,313 6,972
Research and development 13,298 14,571 43,868 56,355
Research and development - licenses acquired 458 700 2,278 1,350
General and administrative 15,383 14,339 45,358 41,260
Total operating expenses 32,518 32,312 101,817 105,937
Income (loss) from operations (23,043) (22,540) (69,967) (80,438)
Other income (expense)        
Interest income 265 738 1,228 1,955
Interest expense and financing fee (6,958) (3,168) (13,142) (8,743)
Change in fair value of derivative liability (803) 0 (1,189) 0
Change in fair value of investments 575 0 575 0
Gain on deconsolidation of Caelum 0 0 0 18,521
Total other income (expense) (6,921) (2,430) (12,528) 11,733
Net loss (29,964) (24,970) (82,495) (68,705)
Less: net loss attributable to non-controlling interests 14,417 12,208 41,264 44,237
Net loss attributable to common stockholders $ (15,547) $ (12,762) $ (41,231) $ (24,468)
Net loss per common share - basic and diluted $ (0.39) $ (0.44) $ (1.19) $ (1.29)
Net loss per common share attributable to non - controlling interests - basic and diluted (0.19) (0.21) (0.59) (0.83)
Net loss per common share attributable to common stockholders - basic and diluted $ (0.20) $ (0.22) $ (0.59) $ (0.46)
Weighted average common shares outstanding - basic and diluted 76,093,211 56,856,821 69,404,499 53,060,565